PINK1 and PARK2 Suppress Pancreatic Tumorigenesis through Control of Mitochondrial Iron-Mediated Immunometabolism

Changfeng Li, Ying Zhang, Xing Cheng, Hua Yuan, Shan Zhu, Jiao Liu, Qirong Wen, Yangchun Xie, Jinbao Liu, Guido Kroemer, Daniel J. Klionsky, Michael T. Lotze, Herbert J. Zeh, Rui Kang, Daolin Tang

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Pancreatic cancer is an aggressive malignancy with changes in the tumor microenvironment. Here, we demonstrate that PINK1 and PARK2 suppressed pancreatic tumorigenesis through control of mitochondrial iron-dependent immunometabolism. Using mouse models of spontaneous pancreatic cancer, we show that depletion of Pink1 and Park2 accelerates mutant Kras-driven pancreatic tumorigenesis. PINK1-PARK2 pathway-mediated degradation of SLC25A37 and SLC25A28 increases mitochondrial iron accumulation, which leads to the HIF1A-dependent Warburg effect and AIM2-dependent inflammasome activation in tumor cells. AIM2-mediated HMGB1 release further induces expression of CD274/PD-L1. Consequently, pharmacological administration of mitochondrial iron chelator, anti-HMGB1 antibody, or genetic depletion of Hif1a or Aim2 in pink1−/− and park2−/− mice confers protection against pancreatic tumorigenesis. Low PARK2 expression and high SLC25A37 and AIM2 expression are associated with poor prognosis in patients with pancreatic cancer. These findings suggest that disrupted mitochondrial iron homeostasis may contribute to cancer development and hence constitute a target for therapeutic intervention. Li et al. demonstrate in mouse models that Pink1 and Park2 deficiency accelerates pancreatic tumorigenesis through mitochondrial iron-dependent immunometabolic dysfunction. These findings shed light on how the autophagy pathway controls iron homeostasis and could have implications for the development of strategies to target mitochondrial iron metabolism in pancreatic cancer.

Original languageEnglish (US)
Pages (from-to)441-455.e8
JournalDevelopmental Cell
Volume46
Issue number4
DOIs
StatePublished - Aug 20 2018
Externally publishedYes

Fingerprint

Carcinogenesis
Iron
Pancreatic Neoplasms
HMGB1 Protein
Tumors
Homeostasis
Inflammasomes
Neoplasms
Tumor Microenvironment
Autophagy
Chelating Agents
Metabolism
Anti-Idiotypic Antibodies
Chemical activation
Cells
Pharmacology
Degradation
Antibodies

Keywords

  • aim2
  • hmgb1
  • immunosuppression
  • inflammasomes
  • iron
  • mitochondrial quality control
  • mitophagy
  • pancreatic tumorigenesis
  • park2
  • pink1

ASJC Scopus subject areas

  • Molecular Biology
  • Biochemistry, Genetics and Molecular Biology(all)
  • Developmental Biology
  • Cell Biology

Cite this

PINK1 and PARK2 Suppress Pancreatic Tumorigenesis through Control of Mitochondrial Iron-Mediated Immunometabolism. / Li, Changfeng; Zhang, Ying; Cheng, Xing; Yuan, Hua; Zhu, Shan; Liu, Jiao; Wen, Qirong; Xie, Yangchun; Liu, Jinbao; Kroemer, Guido; Klionsky, Daniel J.; Lotze, Michael T.; Zeh, Herbert J.; Kang, Rui; Tang, Daolin.

In: Developmental Cell, Vol. 46, No. 4, 20.08.2018, p. 441-455.e8.

Research output: Contribution to journalArticle

Li, C, Zhang, Y, Cheng, X, Yuan, H, Zhu, S, Liu, J, Wen, Q, Xie, Y, Liu, J, Kroemer, G, Klionsky, DJ, Lotze, MT, Zeh, HJ, Kang, R & Tang, D 2018, 'PINK1 and PARK2 Suppress Pancreatic Tumorigenesis through Control of Mitochondrial Iron-Mediated Immunometabolism', Developmental Cell, vol. 46, no. 4, pp. 441-455.e8. https://doi.org/10.1016/j.devcel.2018.07.012
Li, Changfeng ; Zhang, Ying ; Cheng, Xing ; Yuan, Hua ; Zhu, Shan ; Liu, Jiao ; Wen, Qirong ; Xie, Yangchun ; Liu, Jinbao ; Kroemer, Guido ; Klionsky, Daniel J. ; Lotze, Michael T. ; Zeh, Herbert J. ; Kang, Rui ; Tang, Daolin. / PINK1 and PARK2 Suppress Pancreatic Tumorigenesis through Control of Mitochondrial Iron-Mediated Immunometabolism. In: Developmental Cell. 2018 ; Vol. 46, No. 4. pp. 441-455.e8.
@article{758131dfa8a14feb9ba7d54f0e0d3d4f,
title = "PINK1 and PARK2 Suppress Pancreatic Tumorigenesis through Control of Mitochondrial Iron-Mediated Immunometabolism",
abstract = "Pancreatic cancer is an aggressive malignancy with changes in the tumor microenvironment. Here, we demonstrate that PINK1 and PARK2 suppressed pancreatic tumorigenesis through control of mitochondrial iron-dependent immunometabolism. Using mouse models of spontaneous pancreatic cancer, we show that depletion of Pink1 and Park2 accelerates mutant Kras-driven pancreatic tumorigenesis. PINK1-PARK2 pathway-mediated degradation of SLC25A37 and SLC25A28 increases mitochondrial iron accumulation, which leads to the HIF1A-dependent Warburg effect and AIM2-dependent inflammasome activation in tumor cells. AIM2-mediated HMGB1 release further induces expression of CD274/PD-L1. Consequently, pharmacological administration of mitochondrial iron chelator, anti-HMGB1 antibody, or genetic depletion of Hif1a or Aim2 in pink1−/− and park2−/− mice confers protection against pancreatic tumorigenesis. Low PARK2 expression and high SLC25A37 and AIM2 expression are associated with poor prognosis in patients with pancreatic cancer. These findings suggest that disrupted mitochondrial iron homeostasis may contribute to cancer development and hence constitute a target for therapeutic intervention. Li et al. demonstrate in mouse models that Pink1 and Park2 deficiency accelerates pancreatic tumorigenesis through mitochondrial iron-dependent immunometabolic dysfunction. These findings shed light on how the autophagy pathway controls iron homeostasis and could have implications for the development of strategies to target mitochondrial iron metabolism in pancreatic cancer.",
keywords = "aim2, hmgb1, immunosuppression, inflammasomes, iron, mitochondrial quality control, mitophagy, pancreatic tumorigenesis, park2, pink1",
author = "Changfeng Li and Ying Zhang and Xing Cheng and Hua Yuan and Shan Zhu and Jiao Liu and Qirong Wen and Yangchun Xie and Jinbao Liu and Guido Kroemer and Klionsky, {Daniel J.} and Lotze, {Michael T.} and Zeh, {Herbert J.} and Rui Kang and Daolin Tang",
year = "2018",
month = "8",
day = "20",
doi = "10.1016/j.devcel.2018.07.012",
language = "English (US)",
volume = "46",
pages = "441--455.e8",
journal = "Developmental Cell",
issn = "1534-5807",
publisher = "Cell Press",
number = "4",

}

TY - JOUR

T1 - PINK1 and PARK2 Suppress Pancreatic Tumorigenesis through Control of Mitochondrial Iron-Mediated Immunometabolism

AU - Li, Changfeng

AU - Zhang, Ying

AU - Cheng, Xing

AU - Yuan, Hua

AU - Zhu, Shan

AU - Liu, Jiao

AU - Wen, Qirong

AU - Xie, Yangchun

AU - Liu, Jinbao

AU - Kroemer, Guido

AU - Klionsky, Daniel J.

AU - Lotze, Michael T.

AU - Zeh, Herbert J.

AU - Kang, Rui

AU - Tang, Daolin

PY - 2018/8/20

Y1 - 2018/8/20

N2 - Pancreatic cancer is an aggressive malignancy with changes in the tumor microenvironment. Here, we demonstrate that PINK1 and PARK2 suppressed pancreatic tumorigenesis through control of mitochondrial iron-dependent immunometabolism. Using mouse models of spontaneous pancreatic cancer, we show that depletion of Pink1 and Park2 accelerates mutant Kras-driven pancreatic tumorigenesis. PINK1-PARK2 pathway-mediated degradation of SLC25A37 and SLC25A28 increases mitochondrial iron accumulation, which leads to the HIF1A-dependent Warburg effect and AIM2-dependent inflammasome activation in tumor cells. AIM2-mediated HMGB1 release further induces expression of CD274/PD-L1. Consequently, pharmacological administration of mitochondrial iron chelator, anti-HMGB1 antibody, or genetic depletion of Hif1a or Aim2 in pink1−/− and park2−/− mice confers protection against pancreatic tumorigenesis. Low PARK2 expression and high SLC25A37 and AIM2 expression are associated with poor prognosis in patients with pancreatic cancer. These findings suggest that disrupted mitochondrial iron homeostasis may contribute to cancer development and hence constitute a target for therapeutic intervention. Li et al. demonstrate in mouse models that Pink1 and Park2 deficiency accelerates pancreatic tumorigenesis through mitochondrial iron-dependent immunometabolic dysfunction. These findings shed light on how the autophagy pathway controls iron homeostasis and could have implications for the development of strategies to target mitochondrial iron metabolism in pancreatic cancer.

AB - Pancreatic cancer is an aggressive malignancy with changes in the tumor microenvironment. Here, we demonstrate that PINK1 and PARK2 suppressed pancreatic tumorigenesis through control of mitochondrial iron-dependent immunometabolism. Using mouse models of spontaneous pancreatic cancer, we show that depletion of Pink1 and Park2 accelerates mutant Kras-driven pancreatic tumorigenesis. PINK1-PARK2 pathway-mediated degradation of SLC25A37 and SLC25A28 increases mitochondrial iron accumulation, which leads to the HIF1A-dependent Warburg effect and AIM2-dependent inflammasome activation in tumor cells. AIM2-mediated HMGB1 release further induces expression of CD274/PD-L1. Consequently, pharmacological administration of mitochondrial iron chelator, anti-HMGB1 antibody, or genetic depletion of Hif1a or Aim2 in pink1−/− and park2−/− mice confers protection against pancreatic tumorigenesis. Low PARK2 expression and high SLC25A37 and AIM2 expression are associated with poor prognosis in patients with pancreatic cancer. These findings suggest that disrupted mitochondrial iron homeostasis may contribute to cancer development and hence constitute a target for therapeutic intervention. Li et al. demonstrate in mouse models that Pink1 and Park2 deficiency accelerates pancreatic tumorigenesis through mitochondrial iron-dependent immunometabolic dysfunction. These findings shed light on how the autophagy pathway controls iron homeostasis and could have implications for the development of strategies to target mitochondrial iron metabolism in pancreatic cancer.

KW - aim2

KW - hmgb1

KW - immunosuppression

KW - inflammasomes

KW - iron

KW - mitochondrial quality control

KW - mitophagy

KW - pancreatic tumorigenesis

KW - park2

KW - pink1

UR - http://www.scopus.com/inward/record.url?scp=85052321198&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85052321198&partnerID=8YFLogxK

U2 - 10.1016/j.devcel.2018.07.012

DO - 10.1016/j.devcel.2018.07.012

M3 - Article

C2 - 30100261

AN - SCOPUS:85052321198

VL - 46

SP - 441-455.e8

JO - Developmental Cell

JF - Developmental Cell

SN - 1534-5807

IS - 4

ER -